MX366314B - Uso de derivados de insulina por inyecciones con intervalos variables. - Google Patents

Uso de derivados de insulina por inyecciones con intervalos variables.

Info

Publication number
MX366314B
MX366314B MX2013004406A MX2013004406A MX366314B MX 366314 B MX366314 B MX 366314B MX 2013004406 A MX2013004406 A MX 2013004406A MX 2013004406 A MX2013004406 A MX 2013004406A MX 366314 B MX366314 B MX 366314B
Authority
MX
Mexico
Prior art keywords
treating diabetes
insulin injections
injection intervals
injections administered
diabetes melitus
Prior art date
Application number
MX2013004406A
Other languages
English (en)
Other versions
MX2013004406A (es
Inventor
Johansen Thue
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2013004406A publication Critical patent/MX2013004406A/es
Publication of MX366314B publication Critical patent/MX366314B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un derivado de insulina para usarse en el tratamiento de la diabetes tipo 1 o la diabetes tipo 2, en donde el derivado de insulina exhibe un perfil prolongado de acción y en donde el derivado de insulina está adaptado para ser administrado en dosis a intervalos, en donde: al menos uno de los intervalos tiene una duración de i.- al menos 1.3 veces la media de los intervalos, o ii.- no más de 0.85 veces la medida de los intervalos en donde la media de los intervalos es al menos de 12 horas y menos de 36 horas, en donde las dosis no se ajustan entre administraciones y en donde el derivado de la insulina es insulina humana LysB29 (N?-hexadecandioil-y-Glu) des (B30).
MX2013004406A 2010-10-27 2011-10-27 Uso de derivados de insulina por inyecciones con intervalos variables. MX366314B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40720610P 2010-10-27 2010-10-27
EP10189115 2010-10-27
EP11170366 2010-10-27
US201161498645P 2011-06-20 2011-06-20
PCT/EP2011/068870 WO2012055967A2 (en) 2010-10-27 2011-10-27 Treating diabetes melitus using insulin injections administered with varying injection intervals

Publications (2)

Publication Number Publication Date
MX2013004406A MX2013004406A (es) 2013-05-17
MX366314B true MX366314B (es) 2019-07-05

Family

ID=43571114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004406A MX366314B (es) 2010-10-27 2011-10-27 Uso de derivados de insulina por inyecciones con intervalos variables.

Country Status (11)

Country Link
US (1) US20130261051A1 (es)
EP (1) EP2632478B1 (es)
KR (1) KR20130139297A (es)
CN (1) CN103167878A (es)
AU (2) AU2011322495A1 (es)
CA (1) CA2815419A1 (es)
MX (1) MX366314B (es)
PL (1) PL2632478T3 (es)
RS (1) RS59423B1 (es)
SI (1) SI2632478T1 (es)
WO (1) WO2012055967A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP4959005B2 (ja) 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR112014026442A8 (pt) * 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
CN105188736A (zh) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
KR20200130511A (ko) 2013-04-03 2020-11-18 사노피 장시간-작용 제형의 인슐린에 의한 당뇨병의 치료
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US9896496B2 (en) * 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020225129A1 (en) * 2019-05-03 2020-11-12 Diavein Method for treating diabetes and associated disorders with vascular electrical stimulation therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
CN101955527B (zh) * 2003-08-05 2016-04-20 诺沃挪第克公司 新型胰岛素衍生物
ATE519780T1 (de) 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
ES2548393T3 (es) * 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー／エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療

Also Published As

Publication number Publication date
AU2016202917B2 (en) 2017-07-20
WO2012055967A2 (en) 2012-05-03
AU2016202917A1 (en) 2016-05-26
SI2632478T1 (sl) 2019-11-29
WO2012055967A3 (en) 2012-06-21
CN103167878A (zh) 2013-06-19
CA2815419A1 (en) 2012-05-03
AU2011322495A1 (en) 2013-04-11
EP2632478B1 (en) 2019-07-24
US20130261051A1 (en) 2013-10-03
MX2013004406A (es) 2013-05-17
RS59423B1 (sr) 2019-11-29
EP2632478A2 (en) 2013-09-04
KR20130139297A (ko) 2013-12-20
PL2632478T3 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
EA201400030A1 (ru) Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
EA201201657A1 (ru) Лечение диабета
MY167234A (en) Novel glucagon analogues
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
EA201370178A1 (ru) Стабильные составы для парентеральной инъекции пептидных лекарственных средств
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
MX2013011175A (es) Analogos de glucagon novedosos.
MX362503B (es) Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal.
CO2018000196A2 (es) Agente terapéutico para tratar el síndrome de hunter y método de tratamiento
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
MX2013009842A (es) Composicion que comprende receptor gamma activado por proliferador de peroxisoma.
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
BR112013010345A2 (pt) tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
GB2544385A (en) Modulators of caspase-6
BR112022004723A2 (pt) Formulações de insulina e glucagon injetáveis por via subcutânea e métodos de administração

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration